CN112047891A - 一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途 - Google Patents

一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途 Download PDF

Info

Publication number
CN112047891A
CN112047891A CN202010982583.8A CN202010982583A CN112047891A CN 112047891 A CN112047891 A CN 112047891A CN 202010982583 A CN202010982583 A CN 202010982583A CN 112047891 A CN112047891 A CN 112047891A
Authority
CN
China
Prior art keywords
chromone
compound
formaldehyde
ammonium formate
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010982583.8A
Other languages
English (en)
Other versions
CN112047891B (zh
Inventor
罗梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hefei University of Technology
Original Assignee
Hefei University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hefei University of Technology filed Critical Hefei University of Technology
Publication of CN112047891A publication Critical patent/CN112047891A/zh
Priority to US17/388,067 priority Critical patent/US11746092B2/en
Application granted granted Critical
Publication of CN112047891B publication Critical patent/CN112047891B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201Oxygen-containing compounds
    • B01J31/0202Alcohols or phenols
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201Oxygen-containing compounds
    • B01J31/0205Oxygen-containing compounds comprising carbonyl groups or oxygen-containing derivatives, e.g. acetals, ketals, cyclic peroxides
    • B01J31/0208Ketones or ketals
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0244Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0271Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds also containing elements or functional groups covered by B01J31/0201 - B01J31/0231
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/34Other additions, e.g. Monsanto-type carbonylations, addition to 1,2-C=X or 1,2-C-X triplebonds, additions to 1,4-C=C-C=X or 1,4-C=-C-X triple bonds with X, e.g. O, S, NH/N
    • B01J2231/3411,2-additions, e.g. aldol or Knoevenagel condensations
    • B01J2231/346Mannich type reactions, i.e. nucleophilic addition of C-H acidic compounds, their R3Si- or metal complex analogues to aldimines or ketimines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/584Recycling of catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种由以下化学式(I)所示的2‑羟基苯基‑5‑吡嗪基甲酮的合成方法,是称取钯配合物0.048g,0.8413g色酮‑3‑甲醛及甲酸铵2.5719g放入100mL圆底烧瓶中,再加入50mL无水甲醇溶解,加热回流36h后停止反应,用石油醚及二氯甲烷按体积比1:1柱层析,将第一组分点自然挥发后,得淡黄色晶体;该化合物的化学式如下:
Figure DDA0002688083030000011
该化合物(I)的用途,是作为催化剂在二苯亚胺与三甲基硅腈的反应中显示了良好的催化性能,其转化率高达69.1%。

Description

一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途
一、技术领域
本发明涉及一种化合物的制备方法,特别涉及一种吡嗪衍生物的合成方法及用途,确切地说是一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途。
二、背景技术
2-羟基苯基-5-吡嗪基甲酮的合成方法已被大量文献报道,见参考文献【1-3】:
参考文献:
1.Unusual transformation of substituted-3-formylchromones topyrimidine analogues:Synthesis and antimicrobial activities of 5-(o-hydroxyaroyl)pyrimidines,Raj,Tilak et al,Bioorganic&Medicinal ChemistryLetters,23(22),6093-6096;2013.
2.Synthesis of 5H-[1]benzopyrano[4,3-d]pyrimidin-5-one,Loewe,W.,Synthesis,(4),274;1976。
申请人以1mol%钯配合物作催化剂下,催化色酮-3-甲醛与甲酸铵的反应,用无水甲醇做溶剂,得到了一种化合物。所要解决的技术问题是一步合成得到目标产物。
(一)本发明所称的化合物是以下化学式(Ⅰ)所示的化合物:
Figure BDA0002688083010000011
其化学名称:2-羟基苯基-5-吡嗪基甲酮,简称化合物(I).
本化合物(I)的合成方法包括合成和分离,所述的合成是称取0.048g钯配合物,0.8413g色酮-3-甲醛及甲酸铵2.5719g放入100mL圆底烧瓶中,再加入50mL无水甲醇溶解,加热回流36h后停止反应,用石油醚及二氯甲烷按体积比1:1柱层析,将第一组分点自然挥发后,得淡黄色晶体。
合成反应如下:
Figure BDA0002688083010000012
本合成方法一步得到目标产物,工艺简单,操作方便。
其反应机理可推测如下:
色酮-3-甲醛仅在1mol%钯配合物作用下,首先环醚分解,再与及甲酸铵作用,一步反应得到2-羟基苯基-5-吡嗪基甲酮。
四、附图说明
图1 2-羟基苯基-5-吡嗪基甲酮的晶体X-衍射分析图。
五、具体实施方式
1.手性钯配合物的制备
(1)[1,4-(4R)-二异丙基-2-噁唑啉基]苯的制备
在100mL两口瓶中,无水无氧条件下,加入无水ZnCl21.4054g(10.64mmol),40ml氯苯,1,4-二氰基苯5.0236g(39.2mmol),L-缬氨醇16.2075g,将混合物在高温下回流60h,停止反应,减压以除去溶剂,,将剩余物用水溶解,并用CHCl3(20mLx2)萃取,有机相用无水硫酸钠干燥,旋转除去溶剂,将粗产品用石油醚/二氯甲烷(4:1)柱层析,得浅绿色粘稠状液体,产率52%;白色晶体,熔点:48-50℃,[a]5 D=+111.9°(c=0.429,CHCl3);1HNMR(500MHz,CDCl3,27℃),δ(ppm)=7.97(s,4H),4.39~4.43(t,3.18Hz,1H),4.09~4.15(m,2H),1.85~1.86(m,1H),(d,J=6.24Hz,6H),0.86~0.96(d,J=6.24Hz,6H).13CNMR 18.13,19.03,32.85,70.26,72.76,128.10,128.16,130.32,162.82.IR:3273,2976,2960,2932,2889,2869,1643,1512,1469,1408,1382,1366,1350,1320,1296,1276,1214,1180,1108,1077,1047,1014,971,955,900,891,838,726,698,675,659,540.HRMS(EI):m/z(%):calcd forC18H24N2O2:300.1838;found:300.1833。
(2)双{[1,4-(4S)-二异丙基-2-噁唑啉基苯]氯化钯}配合物的制备
100mL两口瓶中,无水无氧条件下,加入氯化钯1.5603g(4.92mmol),1,4-(4R)-二异丙基-2-噁唑啉基苯1.0435g(3.48mmol),氯苯30mL将混合物在高温下回流48h,停止反应,减压以除去溶剂,,将剩余物三氯甲烷及乙醇溶解,自然挥发,得红褐色配合物得晶体,产率:92%;m.p.:>200℃,[a]5 D=+512.8°(c 0.0564,CH3OH);1H NMR(600MHz,CDCl3),δ`ppm8.81(s,8H,ArH),4.61-4.63(m,4H,CH×4),4.53(t,J=9.6Hz,4H,CH×4),4.44(t,J=8.5Hz,4H,CH×4),3.07-3.10(m,4H),1.18and 1.15(dd,J=6.7,7.2Hz,24H,CH3×4);13CNMR(150MHz,CDCl3)δppm 166.8,130.1(×2),129.3,72.0,69.1,30.7,19.0,15.6;νmax(cm-1)3487,3049,2957,2929,2872,1642,1609,1572,1509,1480,1464,1416,1379,1331,1288,1246,1178,1141,1123,1099,1045,1018,959,933,899,854,804,770,722,693,438;Elemental analysis for C36H48N4Cl4O4Pd2,found C 45.26%,H 5.06%,N 5.86%;requires C 45.32%,H 5.24%,N 5.48%;
2.2-羟基苯基-5-吡嗪基甲酮的制备
称取钯配合物0.048g,0.8413g色酮-3-甲醛及甲酸铵2.5719g放入100mL圆底烧瓶中,再加入50mL无水甲醇溶解,加热回流36h后停止反应,用石油醚及二氯甲烷按体积比1:1柱层析,将第一组分点自然挥发后,得淡黄色晶体。晶体(I):产率:52%;m.p:82-84℃;FTIR(cm-1)3408,3044,1621,1602,1574,1465,1432,1416,1335,1299,1242,1219,1191,1178,1149,1115,1035,1001,964,937,919,895,863,826,767,751,715,660,631,586;1H NMR(400MHz,DMSO-d6)δ10.6(s,1H,OH),9.32(s,1H),9.0(s,2H),7.48-7.49(m,2H),6.96-6.99(m,2H);13C NMR(100MHz,DMSO-d6)δ161.66,161.24,134.64,130.69,129.10,128.78,115.83,115,36,84.03,83.82,55.19;Anal.Calcd.for C11H18N2O2:C,66.00;H,4.03;N,13.99.Found:C,65.87;H,4.38;N,13.65;HRMS for C11H18N2O2:Anal.Calcd.:200.0586;Found:200.0596;
该化合物晶体(I)的晶体数据如下:
Figure BDA0002688083010000031
Figure BDA0002688083010000041
晶体典型的键长数据:
Figure BDA0002688083010000042
晶体典型的键角数据:
Figure BDA0002688083010000043
Figure BDA0002688083010000051
二苯甲酮亚胺与三甲基硅腈的缩合反应应用
Figure BDA0002688083010000052
称取1mmol二苯甲酮亚胺和三甲基硅腈0.2mL放置于25mL小烧瓶中,加入2mLTHF及0.1mmol化合物I,常温下搅拌5h,取少量样品做核磁检测,转化率达:69.1%1H NMR(600MHz,CDCl3,27℃)δ7.23–7.59(m,10H),4.10(s,2H)。

Claims (2)

1.一种由以下化学式(I)所示及晶胞参数的2-羟基苯基-5-吡嗪基甲酮的合成方法,其特征在于:所述的合成将是称取钯配合物0.048g,0.8413g色酮-3-甲醛及甲酸铵2.5719g放入100mL圆底烧瓶中,再加入50mL无水甲醇溶解,加热回流36h后停止反应,用石油醚及二氯甲烷按体积比1:1柱层析,将第一组分点自然挥发后,得淡黄色晶体;
该化合物的化学式如下:
Figure FDA0002688083000000011
其晶胞参数如下:在273(2)k温度下,在牛津X-射线单晶衍射仪上,用经石墨单色器单色化的CuKα射线
Figure FDA0002688083000000012
以ω-θ扫描方式收集衍射数据,其特征在于晶体属斜方晶系,空间群:P 21 21 21;晶胞参数:
Figure FDA0002688083000000013
α=90°;
Figure FDA0002688083000000014
β=90°;
Figure FDA0002688083000000015
Figure FDA0002688083000000016
γ=90°。
2.由权利要求1所述的化合物(I)的用途,其特征在于:作为催化剂在二苯亚胺与三甲基硅腈的反应中显示了良好好的催化性能,其转化率高达69.1%。
CN202010982583.8A 2020-07-29 2020-09-17 一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途 Active CN112047891B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/388,067 US11746092B2 (en) 2020-07-29 2021-07-29 Synthetic method and application of 2-hydroxyphenyl-5-pyrazinyl ketone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010745514.5A CN111662236A (zh) 2020-07-29 2020-07-29 一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途
CN2020107455145 2020-07-29

Publications (2)

Publication Number Publication Date
CN112047891A true CN112047891A (zh) 2020-12-08
CN112047891B CN112047891B (zh) 2021-11-30

Family

ID=72392640

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010745514.5A Withdrawn CN111662236A (zh) 2020-07-29 2020-07-29 一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途
CN202010982583.8A Active CN112047891B (zh) 2020-07-29 2020-09-17 一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010745514.5A Withdrawn CN111662236A (zh) 2020-07-29 2020-07-29 一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途

Country Status (2)

Country Link
US (1) US11746092B2 (zh)
CN (2) CN111662236A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113861036A (zh) * 2021-11-08 2021-12-31 合肥工业大学 一种乙二胺高氯酸铜配合物的制备及用途
CN114380765A (zh) * 2022-01-25 2022-04-22 合肥工业大学 一种3-烯丙基洛丹宁二聚体晶体化合物的制备及用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112225652B (zh) * 2020-11-10 2023-07-25 合肥工业大学 一种二水合四羰基环丁烷化合物的制备及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107353221A (zh) * 2017-07-13 2017-11-17 合肥祥晨化工有限公司 一种手性化合物的制备方法及用途
CN110669023A (zh) * 2019-10-17 2020-01-10 合肥工业大学 一种手性噁唑啉铜配合物的用途
CN111018776A (zh) * 2020-02-11 2020-04-17 合肥工业大学 一种吡啶衍生物的合成方法及用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107353221A (zh) * 2017-07-13 2017-11-17 合肥祥晨化工有限公司 一种手性化合物的制备方法及用途
CN110669023A (zh) * 2019-10-17 2020-01-10 合肥工业大学 一种手性噁唑啉铜配合物的用途
CN111018776A (zh) * 2020-02-11 2020-04-17 合肥工业大学 一种吡啶衍生物的合成方法及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TILAK RAJ ET AL.: "Unusual transformation of substituted-3-formylchromones to pyrimidine analogues: Synthesis and antimicrobial activities of 5-(o-hydroxyaroyl)pyrimidines", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113861036A (zh) * 2021-11-08 2021-12-31 合肥工业大学 一种乙二胺高氯酸铜配合物的制备及用途
CN113861036B (zh) * 2021-11-08 2024-04-02 合肥工业大学 一种乙二胺高氯酸铜配合物的制备及用途
CN114380765A (zh) * 2022-01-25 2022-04-22 合肥工业大学 一种3-烯丙基洛丹宁二聚体晶体化合物的制备及用途
CN114380765B (zh) * 2022-01-25 2023-09-29 合肥工业大学 一种3-烯丙基洛丹宁二聚体晶体化合物的制备及用途

Also Published As

Publication number Publication date
CN112047891B (zh) 2021-11-30
US11746092B2 (en) 2023-09-05
US20220033362A1 (en) 2022-02-03
CN111662236A (zh) 2020-09-15

Similar Documents

Publication Publication Date Title
CN112047891B (zh) 一种2-羟基苯基-5-吡嗪基甲酮的合成方法及用途
CN112300178B (zh) 一种5-溴喹唑啉衍生物的制备及用途
CN112062756B (zh) 麦氏酸活化的呋喃和3-吡啶乙胺的Stenhouse供体-受体加合物及其合成方法
CN107880079B (zh) 环状氮杂环双卡宾钯配合物及其制备方法与用途
CN111995544B (zh) 一种4,5-二苯基咪唑啉的合成方法及用途
CN115108930A (zh) 一种氮苯基苯甲酰胺化合物的合成方法及用途
CN110437172A (zh) 一类3,7-二取代吩噁嗪类衍生物及其制备方法
CN112225652B (zh) 一种二水合四羰基环丁烷化合物的制备及用途
CN114349674B (zh) 一种硫脲类化合物及其制备方法
CN113773340B (zh) 一种高效合成9-卤代邻碳硼烷的方法
Sasaki et al. Ruthenium-catalyzed synthesis of vinyl carbamates from carbon dioxide, acetylene, and secondary amines
CN112375105B (zh) 一种n,n-配位的含间位碳硼烷配体的二价镍配合物的应用
CN110314165B (zh) 一种手性噁唑啉钯配合物晶体的用途
CN108976252A (zh) 一种三聚茚基bodipy-香豆素星型化合物的制备方法
CN112174893B (zh) 一种2,4,5-三甲基-1h-咪唑啉甲酸盐的合成方法及用途
CN104059077A (zh) 一种取代基六元瓜环及其制备方法
CN111362815A (zh) 一种化合物及其制备的共价有机框架结构及制备方法
CN112480126B (zh) 一种5-烷基喹唑啉衍生物的制备及用途
CN112430241A (zh) 一种六水合方酸钠配合物
CN114621295A (zh) 一种手性噁唑啉钯配合物晶体及用途
CN111747923B (zh) 一种含冠醚羧酸类化合物bpdc-12-c-4及其制备方法和用途
CN113004248A (zh) 一种钴催化碳氢胺化反应合成咔唑类化合物的方法
CN105153171A (zh) 一种七甲基取代的七元瓜环及合成方法和分离
CN115417799B (zh) 一种硫脲类化合物及其制备方法
Krasavin et al. BF3· OEt2-promoted reaction of isocyanides with o-aminobenzophenones

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant